VANCOUVER, BC, Jan. 12, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“Mind Cure” or the “Company”) is happy to announce the signing of a non-binding letter of intent (the “LOI“) for strategic funding and industrial cooperation with ATMA Journey Centers Inc. (“ATMA“), a Calgary-based group. ATMA is the primary industrial remedy heart in Canada to announce offering psychedelic-assisted remedy for a piece 56 exempt affected person. The LOI is meant to assist Mind Cure safe an fairness place inside ATMA, empowering the Company with entry to a worldwide launch technique for iSTRYM, in addition to worldwide places for translational analysis on novel molecules and remedy protocols.

“ATMA’s clinicians possess a proven track record of advocacy and innovation driving toward the therapeutic benefits of psychedelic medicine for patients in the treatment of mental health and wellness. Mind Cure is extremely excited to join ATMA in the renaissance  that is disrupting mental health care by partnering with one of the pioneers in the therapeutic psychedelics industry,” mentioned Kelsey Ramsden, President & CEO, Mind Cure. “With Mind Cure’s therapeutic tool, iSTRYM, along with ATMA’s pivotal achievement as the care provider for Canada’s most recent section 56(1) exempt patient, mental health care in Canada is making history. We are thrilled to work with the best-in-class to drive our focus on accelerating our research and technology platforms.”

Mind Cure’s partnership with ATMA is an thrilling alternative for researchers and therapists to take part in every of Mind Cure’s analysis applications targeted on ache, neuroregeneration, migraines, and cluster complications. The proposed funding will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the usage of Mind Cure’s proprietary know-how, iSTRYM, to optimize remedy for ATMA purchasers.

The deployment of capital will even advance velocity and scale for knowledge enrichment of iSTRYM, offering the AI-driven platform with entry to affected person knowledge as ATMA targets home and worldwide therapeutic and remedy facilities.

“Psilocybin-assisted therapy offers healing and understanding that is unmatched by traditional methods. Patients dealing with end-of-life anxiety, pain, depression, trauma, and addiction have been at the mercy of ineffective and underwhelming treatments for much too long. The resources are here, and we are extremely grateful to be at the frontlines of this world-changing, innovative, and extremely alleviating solution, to help bring peace to sufferers,” mentioned David Harder, co-CEO, ATMA Journey Centers Inc. “We are witnessing an inflection point for mental health treatment as the commitment to wellness in Canada takes a huge step forward.”

Pursuant to the LOI, the events intend to negotiate the phrases of definitive agreements (the “Definitive Agreements“), which can present for, amongst different issues an preliminary $500,000 funding by Mind Cure in ATMA, participation by Mind Cure in ATMA’s future financings, and the unique use of iSTRYM all through ATMA’s enterprise. There might be no assurance that the Definitive Agreements shall be entered into or that the funding or industrial transactions shall be accomplished on the phrases proposed in the LOI or in any respect.

More at  https://www.psychedelicfinance.com/articles/mind-cure-signs-loi-to-acquire-an-ownership-interest-in-psychedelic-treatment-center-atma-selected-by-section-56-exempt-patient-for-psilocybin-therapy

Source link